<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:mp ids='MP_0005039'>hypoxia</z:mp> has been recognized as a key regulator in renal <z:hpo ids='HP_0005576'>tubulointerstitial fibrosis</z:hpo>, as seen in diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, which is associated with the activation of <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor (HIF)-1α </plain></SENT>
<SENT sid="1" pm="."><plain>We assess here the effects of the <z:chebi fb="0" ids="3095">biguanide</z:chebi>, <z:chebi fb="0" ids="6801">metformin</z:chebi>, on the expression of HIF-1α in diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> using renal proximal tubular cells and type 2 diabetic rats </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: We explored the effects of <z:chebi fb="0" ids="6801">metformin</z:chebi> on the expression of HIF-1α using human renal proximal tubular epithelial cells (HRPTECs) </plain></SENT>
<SENT sid="3" pm="."><plain>Male <z:chebi fb="3" ids="16646">Zucker</z:chebi> diabetic fatty (ZDF; Gmi-fa/fa) rats were treated from 9 to 39 weeks with <z:chebi fb="0" ids="6801">metformin</z:chebi> (250 mg ⋅ kg(-1) ⋅ day(-1)) or insulin </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:chebi fb="0" ids="6801">Metformin</z:chebi> inhibited <z:mp ids='MP_0005039'>hypoxia</z:mp>-induced HIF-1α accumulation and the expression of HIF-1-targeted genes in HRPTECs </plain></SENT>
<SENT sid="5" pm="."><plain>Although <z:chebi fb="0" ids="6801">metformin</z:chebi> activated the downstream pathways of <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase (AMPK), neither the AMPK activator, AICAR, nor the mTOR inhibitor, <z:chebi fb="0" ids="9168">rapamycin</z:chebi>, suppressed <z:mp ids='MP_0005039'>hypoxia</z:mp>-induced HIF-1α expression </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, knockdown of AMPK-α did not abolish the inhibitory effects of <z:chebi fb="0" ids="6801">metformin</z:chebi> on HIF-1α expression </plain></SENT>
<SENT sid="7" pm="."><plain>The <z:chebi fb="0" ids="52726">proteasome inhibitor</z:chebi>, MG-132, completely eradicated the suppression of <z:mp ids='MP_0005039'>hypoxia</z:mp>-induced HIF-1α accumulation by <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>The inhibitors of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> respiration similarly suppressed <z:mp ids='MP_0005039'>hypoxia</z:mp>-induced HIF-1α expression </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> significantly decreased ATP production and oxygen consumption rates, which subsequently led to increased cellular oxygen tension </plain></SENT>
<SENT sid="10" pm="."><plain>Finally, <z:chebi fb="0" ids="6801">metformin</z:chebi>, but not insulin, attenuated tubular HIF-1α expression and pimonidazole staining and ameliorated tubular injury in ZDF rats </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Our data suggest that <z:mp ids='MP_0005039'>hypoxia</z:mp>-induced HIF-1α accumulation in diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> could be suppressed by the antidiabetes drug, <z:chebi fb="0" ids="6801">metformin</z:chebi>, through the repression of oxygen consumption </plain></SENT>
</text></document>